Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarke